Compare GYGY & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GYGY | KYNB |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 27.1M |
| IPO Year | 2026 | 2014 |
| Metric | GYGY | KYNB |
|---|---|---|
| Price | $1.25 | $7.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 12.5K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $6.32 |
| 52 Week High | $11.81 | $9.58 |
| Indicator | GYGY | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 1.77 | 71.71 |
| Support Level | N/A | $6.61 |
| Resistance Level | $4.09 | $8.99 |
| Average True Range (ATR) | 0.47 | 0.31 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 5.38 | 99.24 |
Game Your Game Inc develops and markets AI-based sports performance tracking technology that is prominently focused on the golf industry. Its products include GPS shot tracking hardware, AI algorithms, and a smart coaching app to provide players with real-time insights, recommendations, and personalized performance analytics. The company's technology consists of the GameGolf KZN AI platform, which is an integrated golf performance ecosystem of proprietary shot-tracking hardware and subscription-based software solutions. It generates revenue from the sale of KZN AI hardware device and from recurring annual subscription fees for continued access to the GameGolf App, GameGolf Smart Caddie and the GameGolf platform. Geographically, the company operates mainly in the United States and Europe.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.